Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

NCT03824405 is registered in ClinicalTrials.gov with Botanix Pharmaceuticals as lead sponsor.

NCT NCT03824405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Lead sponsor
Botanix Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2019
Completion date
March 4, 2020
Enrollment
200 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis